The Origin of Botox: From Biological Weapon Research to Beauty Icon

In the early 1820s, a series of strange deaths occurred in Württemberg, in southern Germany. Villagers who had eaten homemade sausages died from muscle paralysis. Their eyelids drooped, swallowing became impossible, and breathing stopped.^[1] The man who investigated these cases was a physician and poet named Justinus Kerner. He collected hundreds of reports, injected sausage extracts taken from patients directly into animals to reproduce the symptoms, and in a paper published in 1822, he speculated that this “sausage poison” acted on the nervous system — and that in very small doses it might actually have therapeutic effects.^[1] It would take another 160 years for that speculation to be realized.

The substance now known as Botox has become the symbol of cosmetic treatment, used in tens of millions of procedures worldwide each year. Yet its history is a remarkable story of entangled threads: toxicology research, Cold War bioweapons development, and a series of accidental medical discoveries.

Tracing the Toxin Back to Sausage

The identity of what Kerner called “sausage poison” was not established until 1895. Belgian bacteriologist Émile van Ermengem investigated a cluster outbreak in the village of Ellezelles, Belgium, where musicians fell ill after eating smoked ham.^[2] He isolated the causative bacterium and named it Clostridium botulinum. The name “botulinum” derives from botulus, the Latin word for sausage — giving scientific form to what Kerner had observed seven decades earlier.

The toxin produced by this bacterium — botulinum toxin — is considered the most potent toxic substance found in nature.^[3] Its mechanism is simple but lethal. The toxin infiltrates the junction where nerves meet muscles and blocks signal transmission. Even when the brain sends the command “move” to a muscle, the signal never arrives. The muscle stops contracting and locks in a relaxed state. The reason foodborne botulism is so dangerous is that it ultimately paralyzes the muscles responsible for breathing.

The Cold War and Bioweapons Research

In the mid-twentieth century, interest in botulinum toxin was ignited not in medical circles but in military ones. During the Second World War, military research institutions in the United States, Canada, and the United Kingdom investigated whether the toxin could be weaponized.^[4] Researchers recognized it as the most potent toxic substance known to science and explored methods of purification and mass production.

In the United States, Edward Schantz at the Fort Detrick biological warfare laboratory in Maryland succeeded in isolating botulinum toxin in purified form for the first time in 1944.^[4] Obtaining the pure toxin meant it could now be studied with precision and administered in controlled doses.

As the Cold War ended and biological weapons development became internationally regulated, however, the direction of this research changed. With its military purpose gone, the toxin awaited an entirely different application.

A Medical Discovery: An Ophthalmologist’s Experiment

The first physician to view botulinum toxin as a therapeutic tool was Alan Scott, an ophthalmologist in San Francisco. In the early 1970s he was searching for a new way to treat strabismus — the condition where the eye turns to one side. The treatment at the time involved surgically cutting or lengthening the eye muscles, a procedure that was invasive and produced unpredictable results.

Scott’s idea was straightforward. The eye misaligns because one muscle contracts too strongly. What if only that muscle could be selectively weakened? He began animal experiments using small quantities of botulinum toxin purified by Edward Schantz in the 1960s.^[5] When the monkey experiments in 1973 confirmed the effect, he obtained FDA authorization and in 1980 administered botulinum toxin to a human patient for the first time.^[5] The results were remarkable. Without surgery — with a single injection — the eye’s alignment was corrected.

Scott’s research transformed the medical community’s view of botulinum toxin. The question had always been one of quantity. A sufficient amount could cause death; an extremely small amount could serve as a precise tool to temporarily paralyze a single target muscle.

Allergan and the Name “Botox”

While Alan Scott continued his clinical trials, the pharmaceutical company Allergan recognized the commercial potential of his drug. In 1988, Allergan acquired the rights to the toxin preparation used in Scott’s research and gave the product the name “Botox.”^[6] The name was coined from the opening letters of “Botulinum Toxin.”

In December 1989, the FDA approved Botox as a treatment for strabismus, blepharospasm (abnormal eyelid contractions), and hemifacial spasm.^[6] It was initially classified as an orphan drug. This approval fell under the biological products regulator CBER, and was later transferred to CDER, where it received a new BLA number (103000). The designation meant patient numbers were too small to expect meaningful revenue. Nobody at the time could have imagined that this drug would become the world’s most widely used cosmetic treatment decades later.

The Accidental Discovery: Wrinkles Disappear

Botox’s transformation into a cosmetic procedure came not from intentional research but from an accidental observation. Jean Carruthers, an ophthalmologist in Vancouver, Canada, was injecting Botox into patients to treat blepharospasm in the 1980s. After treatment, however, patients began showing an unexpected reaction: the wrinkles around the injection sites had disappeared.

One patient, seeking treatment around her eyes, actually asked for injections in her forehead as well. Her reason was that she also wanted her forehead wrinkles gone.^[7] Jean Carruthers brought this observation to her husband Alastair Carruthers, a dermatologist. The two conducted a systematic study together and in 1992 published the first research results on the cosmetic use of botulinum toxin in an academic journal.^[7]

The paper initially attracted little attention. The medical community was skeptical of the very notion of using a toxin for cosmetic purposes. But the results were undeniable. It was gradually established that the glabellar lines — the frown lines between the eyebrows — could be temporarily eliminated with Botox, and the knowledge spread quietly among dermatologists.

FDA Cosmetic Approval and Market Explosion

Throughout the 1990s, approved medical indications for Botox continued to expand. It proved effective for cervical dystonia — abnormal involuntary muscle contractions in the neck — and was also used for axillary hyperhidrosis. In 2000, botulinum toxin type B (brand name Myobloc) received FDA approval for the treatment of cervical dystonia.^[8]

Then came the pivotal moment: on April 15, 2002, the FDA officially approved Botox Cosmetic for the treatment of “moderate to severe glabellar lines.”^[6] This was more than a regulatory milestone — it was an event that shook the entire social perception of cosmetic procedures.

After approval, the number of Botox procedures exploded. Millions of treatments were performed annually in the United States alone, and the practice spread rapidly across Europe, Asia, and Latin America. As of 2025, the global botulinum toxin market is valued at approximately $13.2 billion and is projected to exceed $27.9 billion by 2033.^[9] Within this, the cosmetic segment is growing faster than the therapeutic segment.

From Poison to Medicine: The Paradox of the Mechanism

The most counterintuitive fact in the Botox story is that the basis of its toxicity and the basis of its therapeutic effect are fundamentally identical. The way the toxin causes food poisoning and the way it eliminates wrinkles are exactly the same: it blocks the signal between nerve and muscle. The only difference lies in quantity and precision.

The dosage unit for botulinum toxin is expressed in “U” (units). Treating glabellar lines typically requires 20–40 U, an extraordinarily minute quantity.^[3] Causing food poisoning would require thousands of times more. When this tiny amount temporarily suppresses the contraction of a single muscle, the skin wrinkles created by that muscle disappear along with it. The effect is not permanent. After roughly three to six months, nerve signals begin to transmit again and the muscle gradually recovers.^[3]

This temporariness is also the reason the Botox market exists. If a single treatment produced a permanent effect, repeat procedures would be unnecessary. Botox’s structural characteristic — that the effect fades — generates its own sustained demand.

The Expansion of Medical Applications

While drawing public attention as a cosmetic procedure, the medical applications of botulinum toxin were expanding into a far broader range. Currently, FDA-approved therapeutic indications alone include chronic migraine, overactive bladder, cervical dystonia, hyperhidrosis, and muscle spasticity caused by cerebral palsy, among others.^[10]

Of these, the treatment of chronic migraine is particularly noteworthy. In 2010, the FDA approved Botox for prevention of chronic migraine in patients experiencing headaches on fifteen or more days per month.^[10] The starting point for this research was reports from migraine patients who had received forehead Botox for cosmetic purposes and noticed a reduction in their headaches — yet another accidental discovery.

Researchers continue to demonstrate the effectiveness of botulinum toxin across a range of conditions involving abnormal muscle contractions, including anal sphincter spasms, limb spasticity, and overactive bladder. The “therapeutic toxin” that Kerner imagined in 1822 is being realized today in ways far broader than he could have envisioned, two hundred years on.

Botox and the New Standard of Beauty

Botox’s commercialization did not simply add one more cosmetic procedure to the list. It introduced to the general public, for the first time in practice, the concept that slowing visible aging was achievable. With a procedure taking less than twenty minutes, no surgery, and rapid results, people who would never have considered professional cosmetic surgery began to contemplate Botox.

This dramatically widened the market for cosmetic procedures. Before Botox, most beauty-oriented interventions were surgical and irreversible. Botox offered reversibility: try it, and if you dislike it, simply wait. The removal of that psychological barrier reshaped the global beauty market.

Yet this shift is not universally regarded as positive. Critical perspectives note that the proliferation of Botox has reinforced the equation of “wrinkle-free face equals youth,” turning the natural signs of aging into something requiring correction. Cultural researchers have raised concerns that Botox does not merely erase wrinkles but may be working to homogenize the diversity of facial expression.^[11] In practice, when the forehead muscles remain paralyzed over a long period, the expressions those muscles produce — surprise, sadness, concentration — become limited as well.

Competing Products and Market Diversification

While Botox dominated the early market, other botulinum toxin products have since emerged. Dysport (developed by Ipsen in the United Kingdom), Xeomin (from Merz Pharma in Germany), and South Korea’s Meditoxin have each received FDA or domestic regulatory approval and entered the market.^[9] These products use the same botulinum toxin type A as Botox but differ in their formulation and protein-binding structures.

South Korea occupies a notable position in this market. Korean-developed botulinum toxin products are growing rapidly, particularly in the Asian market, and South Korea is building an increasingly prominent profile as a producer of botulinum toxin on the world stage. The Asia-Pacific region is currently the fastest-growing segment of the global botulinum toxin market, posting annual growth of over eleven percent.^[9]

When Kerner imagined in 1822 that the sausage poison might have therapeutic potential, it was closer to literary speculation than to science. It took 160 years for purified toxin from military laboratories to find its way into an ophthalmologist’s syringe — and then into a cosmetic treatment room. That journey was not the product of one scientist’s brilliant vision. It was the accumulation of wartime fear, a doctor’s curiosity, and an accidental observation by a patient. If one thing remained unchanged throughout that passage from poison to medicine to beauty product, it is the toxin itself. The only thing that changed was the human gaze looking at it.